Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

High Dose Dexamethasone ◽

Faculty Opinions recommendation of Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718100766.793522195 ◽

2016 ◽

Author(s):

Parameswaran Hari ◽

Binod Dhakal

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

High Dose ◽

Open Label ◽

Phase 3 ◽

High Dose Dexamethasone ◽

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(19)32556-5 ◽

2019 ◽

Vol 394 (10214) ◽

pp. 2096-2107 ◽

Cited By ~ 76

Author(s):

Michel Attal ◽

Paul G Richardson ◽

S Vincent Rajkumar ◽

Jesus San-Miguel ◽

Meral Beksac ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Open Label ◽

Phase 3 ◽

KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps8070 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS8070-TPS8070 ◽

Cited By ~ 4

Author(s):

Jatin J. Shah ◽

Sundar Jagannath ◽

María-Victoria Mateos ◽

Antonio Palumbo ◽

Uma Kher ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Open Label ◽

Phase 3 ◽

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

Haematologica ◽

10.3324/haematol.2015.125864 ◽

2015 ◽

Vol 100 (10) ◽

pp. 1334-1339 ◽

Cited By ~ 28

Author(s):

J. F. San Miguel ◽

K. C. Weisel ◽

K. W. Song ◽

M. Delforge ◽

L. Karlin ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Prior Treatment ◽

High Dose ◽

Phase 3 ◽

High Dose Dexamethasone ◽

Depth Of Response

KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma

Annals of Oncology ◽

10.1093/annonc/mdw525.50 ◽

2016 ◽

Vol 27 ◽

pp. viii15-viii16

Author(s):

M.V. Mateos ◽

H. Blacklock ◽

A.O. Rocafiguera ◽

S. Iida ◽

S. Jagannath ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Open Label ◽

Phase 3 ◽

S824 A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

HemaSphere ◽

10.1097/01.hs9.0000561576.58696.ae ◽

2019 ◽

Vol 3 (S1) ◽

pp. 365 ◽

Cited By ~ 4

Author(s):

M. Attal ◽

P.G. Richardson ◽

S.V. Rajkumar ◽

J. San-Miguel ◽

M. Beksac ◽

...

Keyword(s):

Multiple Myeloma ◽

Multicenter Study ◽

Low Dose ◽

Open Label ◽

Phase 3 ◽

Refractory Multiple Myeloma

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

Journal of Hematology & Oncology ◽

10.1186/1756-8722-6-41 ◽

2013 ◽

Vol 6 (1) ◽

Cited By ~ 24

Author(s):

Jian Hou ◽

Xin Du ◽

Jie Jin ◽

Zhen Cai ◽

Fangping Chen ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Chinese Patients ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)

Annals of Oncology ◽

10.1093/annonc/mdw525.51 ◽

2016 ◽

Vol 27 ◽

pp. viii16 ◽

Cited By ~ 2

Author(s):

S. Lonial ◽

M. Ribeiro de Oliveira ◽

H. Yimer ◽

M.V. Mateos ◽

R. Rifkin ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Treatment Naïve

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

Haematologica ◽

10.3324/haematol.2014.112557 ◽

2014 ◽

Vol 100 (2) ◽

pp. e63-e67 ◽

Cited By ~ 17

Author(s):

K. W. Song ◽

M. A. Dimopoulos ◽

K. C. Weisel ◽

P. Moreau ◽

A. Palumbo ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Low Dose ◽

High Dose ◽

Health Related Quality ◽

High Dose Dexamethasone ◽

Related Quality ◽

Health Related

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(09)70284-0 ◽

2010 ◽

Vol 11 (1) ◽

pp. 29-37 ◽

Cited By ~ 639

Author(s):

S Vincent Rajkumar ◽

Susanna Jacobus ◽

Natalie S Callander ◽

Rafael Fonseca ◽

David H Vesole ◽

...

Keyword(s):

Multiple Myeloma ◽

Randomised Controlled Trial ◽

Low Dose ◽

Controlled Trial ◽

Initial Therapy ◽

High Dose ◽

Newly Diagnosed ◽

Open Label ◽

High Dose Dexamethasone ◽

Randomised Controlled